Understanding the key characteristics and use cases of static vs. dynamic supply models
How can new technology platforms optimize Antibody Drug Conjugate Design?
Case Study: OptiForm® Solution Suite Accelerates Bioavailability Enhancement for Early Phase Molecule
Versatility Of Softgel Technology
GPEx® To Increase Production Of Pritumumab
Determination Of API Crystalline State
Formulation Development With Minimal Amount Of API
OptiForm® Solution Suite | Catalent in 90 Seconds
Softgel Technology to Deliver Poorly Soluble APIs | Catalent in 90 Seconds
Global Advantage | Free Trade Zones in China
OptiGel™ Bio Technology | Catalent in 90 Seconds
Comparator and Marketed Drug Sourcing Solutions | Catalent in 90 Seconds
Optimal Drug Delivery Technologies. Better Treatments
Improving Bioavailability with Softgel Technology
Behind the Scenes: Catalent IPO on the NYSE
About Catalent: More Products. Better Treatments. Reliably Supplied
Should your next clinical trial use a new supply model?
The Challenges and Solutions for Non-invasive Macromolecule Delivery
Clinical trial supply strategies for biosimilar studies
Highly Potent API Handling from Optimization through Supply
Optimized Antibody Drug Conjugate Development
Optimizing API Bioavailability and Performance using Particle Size Reduction Technologies